Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

The prevention of corticosteroid-induced bone loss with intermittent cyclical etidronate.

Jenkins EA, Walker-Bone KE, Wood A, McCrae FC, Cooper C, Cawley MI.

Scand J Rheumatol. 1999;28(3):152-6.

PMID:
10380836
4.
5.
6.

Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. A prospective, controlled pilot study.

Wolfhagen FH, van Buuren HR, den Ouden JW, Hop WC, van Leeuwen JP, Schalm SW, Pols HA.

J Hepatol. 1997 Feb;26(2):325-30.

PMID:
9059953
7.

Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss.

Adachi J, Cranney A, Goldsmith CH, Bensen WG, Bianchi F, Cividino A, Craig GL, Kaminska E, Sebaldt RJ, Papaioannou A, et al.

J Rheumatol. 1994 Oct;21(10):1922-6.

PMID:
7837160
8.
9.

Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid induced osteoporosis?

Lems WF, Jacobs JW, Bijlsma JW, van Veen GJ, Houben HH, Haanen HC, Gerrits MI, van Rijn HJ.

Ann Rheum Dis. 1997 Jun;56(6):357-63.

10.

A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid induced bone loss.

Adachi JD, Roux C, Pitt PI, Cooper C, Moniz C, Dequeker J, Ioannidis G, Cawley MI, Jenkins EA, Walker-Bone KE, Pack S, Stephenson GF, Laan RF, Brown J, Geusens P.

J Rheumatol. 2000 Oct;27(10):2424-31.

PMID:
11036840
11.

Intermittent Etidronate partially prevents bone loss in hirsute hyperandrogenic women treated with GnRH agonist.

Zamberlan N, Castello R, Gatti D, Rossini M, Braga V, Fracassi E, Adami S.

Osteoporos Int. 1997;7(2):133-7.

PMID:
9166393
12.

Longterm effect of intermittent cyclical etidronate therapy on corticosteroid-induced osteoporosis in Japanese patients with connective tissue disease: 7-year followup.

Sato S, Takada T, Katsuki Y, Kimura N, Kaneko Y, Suwa A, Hirakata M, Kuwana M.

J Rheumatol. 2008 Jan;35(1):142-6. Epub 2007 Nov 15.

PMID:
18050368
13.

36 month intermittent cyclical etidronate treatment in patients with established corticosteroid induced osteoporosis.

Sebaldt RJ, Ioannidis G, Adachi JD, Bensen WG, Bianchi F, Cividino A, Gordon M, Kaminska E, Scocchia T, Petrie A, Stephenson GF, Goldsmith CH.

J Rheumatol. 1999 Jul;26(7):1545-9.

PMID:
10405943
14.

Effect of intermittent cyclical etidronate therapy on corticosteroid induced osteoporosis in Japanese patients with connective tissue disease: 3 year followup.

Sato S, Ohosone Y, Suwa A, Yasuoka H, Nojima T, Fujii T, Kuwana M, Nakamura K, Mimori T, Hirakata M.

J Rheumatol. 2003 Dec;30(12):2673-9.

PMID:
14719212
15.

Cyclical etidronate therapy for prevention of postmenopausal bone loss: a 1-year open-label follow-up study.

Fogelman I, Herd RJ, Blake GM, Balena R.

Calcif Tissue Int. 2000 May;66(5):348-54.

PMID:
10773104
16.

[The clinical benefits to bone mineral density were shown by cyclical oral etidronate administration in steroid induced osteoporosis].

Nakamura T, Maekawa S, Morinobu S, Morinobu A, Koshiba M, Yamauchi M, Sugimoto T, Kumagai S.

Ryumachi. 2002 Aug;42(4):666-75. Japanese.

PMID:
12355861
17.

A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.

Fukunaga M, Kushida K, Kishimoto H, Shiraki M, Taketani Y, Minaguchi H, Inoue T, Morita R, Morii H, Yamamoto K, Ohashi Y, Orimo H; Risedronate Phase III Research Group.

Osteoporos Int. 2002 Dec;13(12):971-9.

PMID:
12459940
18.

Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group.

Roux C, Oriente P, Laan R, Hughes RA, Ittner J, Goemaere S, Di Munno O, Pouill├Ęs JM, Horlait S, Cortet B.

J Clin Endocrinol Metab. 1998 Apr;83(4):1128-33.

PMID:
9543129
19.

Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.

Lems WF, Lodder MC, Lips P, Bijlsma JW, Geusens P, Schrameijer N, van de Ven CM, Dijkmans BA.

Osteoporos Int. 2006;17(5):716-23. Epub 2006 Feb 3.

PMID:
16463007
20.

Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis.

Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, Kendler DL, Lentle B, Olszynski W, Ste-Marie LG, Tenenhouse A, Chines AA.

N Engl J Med. 1997 Aug 7;337(6):382-7.

Items per page

Supplemental Content

Write to the Help Desk